Delivery Order SPE2DB22D2211-SPE2DB25FSCCW
- Not listed
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for the supply of Dupixent 300 mg/2 ml syringes (2 ml). The contract is valued at $3,960.88 with a firm fixed price and an ultimate completion date of July 31, 2025. This award represents a competitive, non-set-aside procurement and is classified as a child contract, indicating it derives from a larger contract vehicle. The Defense Logistics Agency,...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $10,302.48 on July 25, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract is competitively awarded with no set-aside designation and carries an ultimate completion date of July 28, 2025. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for $19,042.85 to supply Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 6, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 21, 2025, for the supply of Dupixent 300 mg/2 ml syringes. The contract is valued at $22,619.31 and represents a firm fixed-price delivery order with an ultimate completion date of July 22, 2025. The performance location is the company's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside award, indicating it was competitively awarded. The delivery order is issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency (DLA) for Dupixent 200 mg/1.14 ml pen auto-injectors. The contract is valued at $1,935.84 with a firm fixed price structure and an ultimate completion date of August 5, 2025. This non-competitive delivery order was issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $17,017.67 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's headquarters location...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order valued at $26,119.30 for Dupixent 300 mg/2 ml pen (2 ml) under a firm fixed price contract with the Defense Logistics Agency's Medical Supply Chain. The award was made on July 30, 2025, with an ultimate completion date of July 31, 2025, and represents a non-set-aside, competitively awarded contract. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $17,094.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a $4,171.54 delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 4, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order falls under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,144.72 by the Defense Logistics Agency on August 4, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL). This competitively awarded, firm fixed-price contract carries no set-aside designation and is scheduled for completion by August 5, 2025. The contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCCWDelivery Order
AmerisourceBergen Drug Corp, headquartered in Conshohocken, PA, was awarded a delivery order by the Defense Logistics Agency on August 4, 2025, for Dupixent 200 mg/1.14 mL syringes valued at $8,195.94. This firm fixed-price contract, with an ultimate completion date of August 5, 2025, carries no set-aside designation and represents a competitively awarded procurement. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $1 billion prime vendor agreement designated SPE2DX and running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's substantial role within the DLA Medical Supply Chain reflects its capability to meet federal procurement requirements across a diverse portfolio of therapeutic domains, including specialty medications, biologics, and medical devices. This award of Dupixent, a biologic immunosuppressant used to treat conditions such as atopic dermatitis and eosinophilic diseases, demonstrates continued reliance on AmerisourceBergen for delivering specialized pharmaceutical commodities to support military personnel and veteran healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.2k | 8/4/25 |